Polypharmacy and predictors of high level polypharmacy in patients with diabetic nephropathy in a tertiary care hospital

Josephine V. Jose¹, Padmini Devi²*, Renuka Satish³

¹Department of Pharmacology, Believers Church Medical College Hospital, Thiruvalla, Kerala, India
²Department of Pharmacology, ³Department of Nephrology, St. John's Medical College, Bangalore, Karnataka, India

Received: 08 April 2019 Accepted: 07 May 2019

*Correspondence to: Dr. Padmini Devi, Email: p.nidhin@hotmail.com

ABSTRACT

Background: Diabetic Nephropathy (DN) is the leading cause of end-stage renal disease. Polypharmacy is common in DN as pharmacotherapy is complex with multimorbidity. The objectives of the study are to assess the prevalence and patterns of polypharmacy and to determine the predictors of high-level polypharmacy among patients with diabetic nephropathy in a tertiary care hospital.

Methods: A prospective observational study was conducted among adult patients with DN visiting nephrology outpatient department (March 2015 to August 2016). Data on demography, disease characteristics, and treatments were collected. Baseline data were summarized using descriptive statistics. Categorical variables and predictors of polypharmacy were analysed using Chi-square tests and multivariate logistic regression respectively.

Results: Mean age of patients was 58.14±10.44 years with male preponderance (72.7%). A majority of patients had comorbidities (76%). Hypertension was the most common co-morbidity (98.7%). Majority (64%) were in DN stage 4-5 and 58% of patients were undergoing hemodialysis. Mean number of drugs prescribed was 9.25±2.5. Anti-hypertensives (95.3%) were the major drug class prescribed. Polypharmacy (>5 drugs) was noticed in 95.3% patients and high-level polypharmacy (>10 drugs) in 46.7%. Presence of ≥3 comorbidities is a significant predictor of high-level polypharmacy (OR-1.414; 95% CI (1.008, 1.982), p=0.045).

Conclusions: Polypharmacy was noticed in a majority of patients with high level polypharmacy in more than one third of patients with DN. Presence of ≥3 comorbidities were found to be significant predictor of high-level polypharmacy.

Keywords: Diabetic nephropathy, India, Multimorbidity, Polypharmacy, Predictors

INTRODUCTION

Diabetic nephropathy (DN) is one of the common microvascular complications of diabetes mellitus. It is a leading cause of end-stage renal disease and a contributor to significant morbidity and mortality in patients with diabetes.¹ The mortality burden in DN is 23.5% as compared to non-diabetics (6.1%, P=0.072) in India.² Slowing the rate of disease progression in the early stages of DN is a major goal, together with monitoring and correcting its complications and co morbidities, and treating the underlying disease. Pharmacotherapy for DN is complex as it is usually associated with multimorbidity. Multimorbidity can present several challenges in patient care particularly with higher numbers of coexisting conditions and related polypharmacy.³ Polypharmacy is defined as the concurrent prescribing of >5 drugs.⁴ Polypharmacy is common in DN as there are multiple co morbidities and it can lead to problems like non adherence, adverse drug reactions, drug interactions and increased cost of therapy.⁵
The objectives of this study were to assess the prevalence and patterns of polypharmacy and its predictors. No studies were identified from India using the MeSH terms (DN, Polypharmacy, drug, India) in Pubmed from 2004-2014 with the best of our knowledge. This study was expected to provide a comprehensive review on polypharmacy in DN, to recommend suggestions in comparison with evidence-based therapies.

METHODS

Authors conducted a prospective, observational study at an Indian tertiary care hospital with a large dialysis facility over 18 months. Recruitment was done from March 2015 to August 2016. Ethics approval for the study is obtained from Institutional Ethics Review Board (IERB). The IEC reference number for the study is 115/2015. The study was explained in the language understood by the patient and informed consent was obtained. Authors included patients diagnosed with diabetic nephropathy all stages, aged ≥18 years irrespective of whether they were on dialysis. Authors excluded patients undergoing renal transplant and peritoneal dialysis. Authors collected demographic, laboratory and treatment data. Demographic data includes age, gender and socio-economic status (education, income, occupation). Medical history includes family history, disease characteristics, stage of disease CKD and DN, duration of the disease, comorbidities, presence of dialysis and frequency of dialysis.

According to literature, mean no. of drugs per patient in DN is 7±2.8 With relative precision of 5% and CI = 95%, assuming 20% drop outs, sample size is estimated as 150 patients to assess the prevalence and patterns of polypharmacy in DN.

Baseline data were summarized as mean±SD. Descriptive statistics were used to analyze data on demography, disease characteristics, key laboratory investigations. Data on the prevalence of polypharmacy, were analysed using descriptive statistics. Two groups were formed based on poly pharmacy (with polypharmacy and without polypharmacy) and the categorical variables like gender, age category, socio-economic status, stage of DN and CKD, presence or absence of dialysis were compared between the groups using Chi-squared tests. To assess the predictors of polypharmacy in patients with DN, binary logistic regression followed by multivariate logistic regression analysis was performed. High level polypharmacy (concurrent prescription of ten or more drugs) was taken as the dependent variable and independent variables used were the patient characteristics (age, sex, socio-economic status) and disease characteristics (stages of DN and CKD, comorbidities and presence of dialysis). A p value <0.05 will be considered significant for all tests. Statistical analysis was performed using commercially available software, Statistical Package for the Social Sciences version 16.0 software (SPSS Inc, Chicago, IL, USA).

RESULTS

Among the 150 DN patients recruited, 109 (72.7 %) were males. The mean age was 58.14±10.44 years. Majority of the patients had a family history of diabetes, 93 (62.0%), followed by hypertension 60 (40.0%) and chronic kidney disease 16 (10.7%) respectively (Table 1).

Authors classified the patients according to stages of DN and CKD. Hypertension was the most common comorbidity seen in 148 (98.7%) DN patients, followed by diabetic retinopathy, present in 91 (60.7) patients.

| Table 1: Baseline characteristics. |
|-----------------------------------|
| **Baseline characteristics**                          | **No. of patients (N=150)** |
| Mean age in years ±SD             | 58.14±10.44 |
| Gender, n (%)                     | Male 109 (72.7) |
|                                  | Female 41 (27.3) |
| Age category, n (%)               | <60 years 76 (50.7) |
|                                  | ≥60 years 74 (49.3) |
| Place of residence, n (%)         | Rural 47 (31.3) |
|                                  | Urban 103 (68.7) |
| Habits                            | Smoking 32 (21.3) |
|                                  | Alcohol 32 (21.3) |
|                                  | Tobacco chewing 04 (02.7) |
| Socio-economic status, n (%)      | Rich 15 (10.0) |
|                                  | Upper middle 45 (30.0) |
|                                  | Lower middle 62 (41.3) |
|                                  | Upper lower 24 (16.0) |
|                                  | Lower (poor) 04 (02.7) |
| Family History, n (%)             | Diabetes 93 (62.0) |
|                                  | Hypertension 60 (40.0) |
|                                  | Chronic kidney disease 16 (10.7) |
Other cardiovascular co-morbidities like coronary artery disease and stroke were seen in 36 (24.0%) and 06 (4.0%) patients respectively. Hypothyroidism was reported in 32 (21.5%) patients and liver disease in 15 (10.0%) patients.

There were other comorbidities like diabetic foot in 16 (10.7%) patients, seizure disorder in 3 (02.0%), bronchial asthma in 2 (01.3%) and psychiatric illness in 1 (0.7%) patient. Details are presented in Table 2.

Among the 150 patients with DN, 87 patients (58.0%) were undergoing hemodialysis as the renal replacement therapy. 50 patients (57.5%) were undergoing dialysis twice a week, 35 patients (40.2) three times a week, 2 patients (02.3%) once a week (Table 2).

Table 2: Disease characteristics of DN patients at baseline.

| Disease characteristics          | n (%)                  | N=150 |
|----------------------------------|------------------------|-------|
| Stages of CKD, n (%)             |                        |       |
| Stage I                          | 17 (11.3)              |       |
| Stage II                         | 09 (06.0)              |       |
| Stage III                        | 23 (15.3)              |       |
| Stage IV                         | 13 (08.7)              |       |
| Stage V                          | 88 (58.7)              |       |
| Stages of DN, n (%)              |                        |       |
| Stage I                          | 16 (10.7)              |       |
| Stage II                         | 11 (07.3)              |       |
| Stage III                        | 27 (18.0)              |       |
| Stage IV                         | 11 (07.3)              |       |
| Stage V                          | 85 (56.7)              |       |
| Comorbidities n (%)              |                        |       |
| Hypertension                     | 148 (98.7)             |       |
| Diabetic retinopathy             | 91 (60.7)              |       |
| Coronary Artery Disease          | 36 (24.0)              |       |
| Thyroid hypothyroidism           | 32 (21.5)              |       |
| Diabetic foot                    | 16 (10.7)              |       |
| Liver disease                    | 15 (10.0)              |       |
| Seizure                          | 03 (02.0)              |       |
| Stroke                           | 06 (04.0)              |       |
| Dyslipidemia                     | 06 (04.0)              |       |
| Bronchial asthma                 | 02 (01.3)              |       |
| Psychiatric illness              | 01 (00.7)              |       |
| Dialysis history, n (%)          |                        |       |
| No. of patients underwent dialysis| 87 (58.0)             |       |
| Haemodialysis frequency          |                        |       |
| 1 time/week                      | 02 (02.3)              |       |
| 2 times/week                     | 50 (57.5)              |       |
| 3 times/week                     | 35 (40.2)              |       |

There are 24% of the patients with single comorbidity, 36.4% of the patients had 2 comorbidities, 28.7% of patients had 3 comorbidities, 6.7% had four comorbidities and 4% of the patients had 5 comorbidities (Figure 1).

Mean number of drugs that the patients received in this study was 9.25±2.54. Anti-hypertensives (95.3%) were the major drug class prescribed.

Polypharmacy (patients who receive ≥5 drugs) was present in 143 patients (95.3%) high level polypharmacy (≥10 drugs) was noticed in 70 patients (46.70%) and low-level polypharmacy (≥5 drugs, but <10 drugs) in 73 patients (48.70%) (Table 3).

Table 3: Pattern of polypharmacy in DN patients.

| Parameter                  | No. of patients (N = 150) | %  |
|----------------------------|---------------------------|----|
| Mean no. of drugs (SD)     | 9.25 (2.544)              |    |
| Polypolyparmacy            | 143                       |    |
| Level of polypharmacy      |                           |    |
| Low                        | 73                        | 48.70 |
| High                       | 70                        | 46.70 |

Chi squared test was done to compare the characteristics of patients with polypharmacy and no polypharmacy. There is significant increase in the occurrence of polypharmacy with higher stages of DN (p =0.014) (Table 4). Bivariate analysis identified DN stages 4-5 (p=0.026), CKD stages 4-5 (p=0.005), presence of dialysis (p=0.024) as significant predictors of high-level polypharmacy.

On multivariate logistic regression analysis, presence of ≥3 comorbidities (OR=1.414, p=0.045) was found to be a significant predictor of high-level polypharmacy in patients with DN (Table 5).

**DISCUSSION**

To the best of our knowledge, this study is the first follow up comprehensive study in South India which evaluated the patterns and determinants of polypharmacy in patients with DN. The mean age of the patients in this study was 58.14 (+10.44) years with 72.7% males. This was comparable to the mean age of patients with overt nephropathy in CURES.
study conducted in Chennai where the mean age was 57±9 yrs and a majority of patients were males (52%).

Table 4: Comparison of characteristics of patients with polypharmacy and no polypharmacy.

| Parameters         | Polypharmacy | No polypharmacy | P value |
|--------------------|--------------|-----------------|---------|
| Age category       |              |                 |         |
| ≥60 years          | 70           | 6               | 0.495   |
| <60 years          | 73           | 1               |         |
| Gender             |              |                 |         |
| Male               | 103          | 6               | 0.705   |
| Female             | 38           | 3               |         |
| Dialysis           |              |                 |         |
| Present            | 83           | 3               | 0.127   |
| Absent             | 57           | 6               |         |
| Socioeconomic status |          |                 |         |
| Upper              | 13           | 2               |         |
| Upper middle       | 44           | 1               | 0.453   |
| Lower middle       | 58           | 4               |         |
| Lower middle       | 22           | 2               |         |
| Lower              | 15           | 1               |         |
| Stages of CKD      |              |                 | 0.130   |
| Stage I            | 15           | 2               |         |
| Stage II           | 08           | 1               |         |
| Stage III          | 22           | 4               |         |
| Stage IV           | 11           | 2               |         |
| Stage V            | 85           | 0               |         |
| Stage of DN        |              |                 |         |
| Stage I            | 14           | 2               |         |
| Stage II           | 10           | 1               |         |
| Stage III          | 26           | 1               |         |
| Stage IV           | 08           | 3               |         |
| Stage V            | 83           | 2               |         |
| Comorbidities      |              |                 |         |
| <3                 | 84           | 8               | 0.154   |
| ≥3                 | 57           | 1               |         |

*Compared using Chi-Square test, for cells with the count <5 Fisher's exact test was used. p ≤0.05 is considered statistically significant.

Table 5: Predictors of high-level polypharmacy in patients with DN.

| Characteristics          | Bivariate analysis | Multivariate analysis |
|--------------------------|--------------------|-----------------------|
|                          | OR                 | 95% CI                | P value  | OR                 | 95% CI                | P value  |
| Age category             |                    |                       |         |                    |                       |         |
| <60 years                | Ref 1.150          |                       |         | 0.596-2.216        | 0.139                 | 0.790    | 0.383-1.630 | 0.523   |
| ≥60 years                | 1.167              | 0.558-2.439           | 0.682   | -                   | -                     | -                   |
| Gender                   |                    |                       |         |                    |                       |         |           |         |
| Female                   | Ref 1.354          | 0.693-2.645           | 0.375   | -                   | -                     | -                   |
| Male                     | 1.939              | 0.981-3.832           | 0.057   | 1.414               | 1.008-1.982           | 0.045*   |
| SES category             |                    |                       |         |                    |                       |         |           |         |
| Lower                    | Ref 1.150          |                       |         | 0.596-2.216        | 0.139                 | 0.790    | 0.383-1.630 | 0.523   |
| Upper                    | 1.167              | 0.558-2.439           | 0.682   | -                   | -                     | -                   |
| No. of comorbidities     |                    |                       |         |                    |                       |         |           |         |
| < 3                      | Ref 1.214          | 1.100-4.459           | 0.026   | 0.333               | 0.084-1.324           | 0.119   |
| ≥3                       | 2.862              | 1.373-5.966           | 0.005   | 3.652               | 0.956-13.943          | 0.058   |
| Stage of DN              |                    |                       |         |                    |                       |         |           |         |
| Stage 1-3                | Ref 2.214          | 1.100-4.459           | 0.026   | 0.333               | 0.084-1.324           | 0.119   |
| Stage 4-5                | 2.862              | 1.373-5.966           | 0.005   | 3.652               | 0.956-13.943          | 0.058   |
| CKD stage                |                    |                       |         |                    |                       |         |           |         |
| Stage 1-3                | Ref 2.196          | 1.109-4.348           | 0.024   | 0.677               | 0.205-2.234           | 0.522   |
| Stage 4-5                | 2.862              | 1.373-5.966           | 0.005   | 3.652               | 0.956-13.943          | 0.058   |

*Binary logistic regression followed by multivariate logistic regression is done and p < 0.05 is considered statistically significant.

In this study, 11.3%, 0.6%, 15.3%, 8.7% and 58.7% patients were in CKD stage 1, 2, 3, 4 and 5 respectively. In the Indian CKD registry, the proportion of DN patients in CKD stage 1, 2, 3, 4 and 5 are 1.7%, 4.2%, 20.2%, 27.2% and 47.3% respectively. The proportion of CKD stage 5 patients in our study was higher than other stages which is
comparable to the above registry. The patients in this study on an average underwent 8 dialysis sessions per month which was comparable with the study by Satyavani K et al, done in a South Indian state.8

KDOQI (Kidney disease outcomes quality initiative) clinical practice guideline recommends 3-4 dialysis sessions per patient per week.9 This was not affordable to many patients as around 90% belonged to lower to middle class socioeconomic strata in this study. Among the patients who were undergoing dialysis in this study, 55.7% belong to lower socioeconomic status. Satyavani K et al, showed that among patients on dialysis, 80% had monthly income below INR 20,000 and 47% below INR 10,000. The cost of diabetes treatment is an out-of-pocket expenditure for many patients in developing countries such as India. In the absence of insurance policies for diseases such as diabetes and meager financial support from the public health-care sector, patients spend from their personal savings and face a huge financial crisis.

Arterial hypertension is a main risk factor for the development of DN. In this study, hypertension was the most common comorbidity present in 148 patients (98.7%) as similar to CURES study that showed 86.7% of patients had hypertension with overt nephropathy.7

In this study, about 58% of the patients were on hemodialysis and 57.5% of them were undergoing dialysis 2 times per week while 40.2% underwent dialysis 3 times per week, according to the UK clinical guidelines on hemodialysis.10

The mean no. of drugs per day in our study was 9.25±2.54. This is comparable to the study on CKD patients in Brazil where the average no. of drugs per day was 8.5±4.3.11 In this study, anti-hypertensives were the most commonly prescribed (95.3%) drugs.

Since diabetic nephropathy is usually associated many comorbidities like hypertension, dyslipidemia, CAD, heart failure etc, the treatment of this condition is complex involving multiple medications. So, polypharmacy is common in this condition. Multimorbidity in the general population is associated with polypharmacy.12 In this study, 95.3% of patients had polypharmacy, out of which 46.7% had high level polypharmacy (prescribed ≥10 drugs). The prevalence of polypharmacy was 56.72% in patients with CKD in a study conducted among 1300 patients aged above 60 years in US.13 In this study, authors got the number of comorbidities ≥3 as a significant predictor of high-level polypharmacy. The patients with DN have multiple comorbidities that predispose to multiple medications.14

Authors have conducted a comprehensive, prospective study that looked at demography, clinical features and pattern of polypharmacy in patients with DN. It was carried out on an estimated sample size of 150 DN patients. Being a tertiary care setting, authors had representation from different sections of the society. Multimorbidity was found to be a significant predictor of polypharmacy.

Present study provided reliable and relevant information on multimorbidity and polypharmacy among Indian patients with DN and this could be used as a support for better patient management and also for future research.

Funding: No funding sources
Ethical approval: The study was approved by the Institutional Ethics Review Board (No. 115/2015)

REFERENCES

1. Soetikno V, Arozal W, Louisa M, Setiabudy R. New insight into the molecular drug target of diabetic nephropathy. Int J Endocrinol. 2014;9:968681.
2. Mohan V, Sandeep S. Epidemiology of type 2 diabetes: Indian scenario. Ind J Med Res. 2007:217-30.
3. Emma W, Chris S, Bruce G, Cliona L, Tom F, Susan SM, et al. Managing patients with multimorbidity in primary care. BMJ. 2015:350.
4. Keane WJ, Zhang Z. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RenalA study. Clin J Am Soc Nephrol. 2006;1:761-7.
5. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145-5.
6. Devi DP, George J. Diabetic nephropathy: prescription trends in tertiary care. Indian J Pharm Sci. 2008;70(3):374-8.
7. Unnikrishnan R, Rema M, Pradeepa R, Deepa M, Shanthirani CS, Deepa R. Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45). Diab Care. 2007:30:2019-24.
8. Satyavani K, Kothandan H, Jayaraman M, Viswanathan V. Direct costs associated with chronic kidney disease among type 2 diabetic patients in India. Indian J Nephrol. 2014;24:141-7.
9. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015:66(5):884-930.
10. Mactier R, Hoenich N, Breen C. Renal Association Clinical Practice Guideline on haemodialysis. Nephron Clin Pract. 2011:118.
11. Magacho EJ, Ribeiro LC, Chaoubah A, Bastos MG. Adherence to drug therapy in kidney disease. Braz J Med Biol Res. 2011;44:258-62.
12. Corsonello A, Pedone C, Corica F, Incalzi RA. Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag. 2007;3:197-203.
13. Sutaria A, Liu L, Ahmed Z. Multiple medication (polypharmacy) and chronic kidney disease in patients aged 60 and older: a pharmaco epidemiologic...
perspective. Ther Adv Cardiovasc Dis. 2016;10(4):242-50.

14. Strehblow, C, Smeikal M, Fasching P. Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients. Vienna Clin Weekly. 2014;126:195-200.

Cite this article as: Jose JV, Devi P, Satish R. Polypharmacy and predictors of high level polypharmacy in patients with diabetic nephropathy in a tertiary care hospital. Int J Basic Clin Pharmacol 2019;8:1371-6.